FertilAI

Founded in 2021, Israel-based FertilAI develops technologies to improve the success rate of fertility treatments, enhance patient experience, and increase clinics' ability to scale by AI technology. Its core offering is Fertilane, an AI-powered clinical platform that predicts natural cycle ovulation and assists physicians in making decisions about fertility treatments for their patients. The platform utilizes AI algorithms to generate treatment recommendations, including ovulation tracking, intrauterine insemination (IUI), hormonal injections, and frozen embryo transfer (FET). These algorithms are integrated into the Fertilane platform, which facilitates effective communication between clinics, doctors, and patients through dedicated applications and web interfaces.
 

As of March 2024, the company reported that Fertilane increases the average number of eggs retrieved for fertilization into embryos by 30% and clinical pregnancy rates by 8%. The platform also reduces the number of required blood tests and ultrasound scans by 30%, streamlining the treatment process for patients. FertilAI's natural cycle ovulation prediction algorithm, developed based on clinical research, boasts a 99% accuracy rate in predicting the precise ovulation date (November 2024). This algorithm requires only two to three blood tests and no ultrasounds, compared to the traditional method that typically involves three to five blood tests and ultrasounds.